Accumulate Sun Pharma, target Rs 873: Prabhudas Lilladher
Sun Pharma's subsidiary Taro Pharma's FY16 Annual Report analysis observations are, a) price rise in products with marginally declining volume b) high asset-turnover ratio c) high chargebacks/rebates/discounts d) higher working capital and d) Lower addition in net operating cash-flow in comparison to increase in sales Sun Pharma enters into derma segment
The company will co-promote Suncros brand across prescription and consumer channels to drive growth Sun Pharma will focus on dermatology as the fourth engine of growth for its OTC business. As part of this growth strategy, the company has announced roll-out of its first dermatology product, Suncros through the Global Consumer Healthcare business. Currently marketed []
Sun Pharma enters dermatology segment to expand retail offering
The generic drug maker launched a new dermatology productSuncrosa sunscreen brand which was earlier available only as a branded prescription product Sun Pharma focuses on dermatology as additional engine of growth for Global Consumer Healthcare (GCH) business
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated June 08, 2016 titled "Sun Pharma focuses on dermatology as additional engine of growth for Global Consumer Healthcare (GCH) business". Declaration regarding Audit Report with unmodified opinion
Sun Pharmaceutical Industries Ltd has submitted to BSE a copy of Declaration regarding Audit Report with unmodified opinion. Sun Pharma announces divestment of US manufacturing units
Divests two units to Frontida BioPharm
Sun Pharma to sell its US manufacturing units to Frontida BioPharm
Sun Pharma will sell its two oral solid dosage manufacturing units in the US along with 15 related pharmaceutical products for an undisclosed amount Sun Pharma announces divestment of US manufacturing units
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated June 04, 2016 titled "Sun Pharma announces divestment of US manufacturing units". Accmulate Sun Pharma, target Rs 873: Prabhudas Lilladher
Management guided 8-10% sales growth and EBITDA margin will be impacted with higher R&D; costs of above 8% of sales,"
Sun Pharma guides 8% to 10% sales growth for FY17
For the full year, Sun notched up net sales/total income of Rs 27744 crore, growing 2% over the corresponding year last year.